

Press Release

**“Creating the future: New challenges in biology and medicine”
Ipsen gathers a panel of world-renowned scientists**

Paris (France), 19 January 2009 - To mark the occasion of moving its new corporate headquarters to Boulogne-Billancourt, near Paris, Ipsen holds today an international scientific symposium dedicated to the new challenges of biomedical research.

Recent scientific advances have progressed the field of knowledge and revealed the unbelievable complexity of disease mechanisms in cancer and brain diseases, as well as in immune system and endocrine regulation disorders. The understanding of these mechanisms represents a major challenge for the future of medical progress, but they also stand as an ethical duty. As a world-class player in research and innovation, Ipsen is a key contributor to the ongoing biological revolution and is committed to supporting basic research.

This unique event gathers prominent international academics who have contributed to major advances in life sciences over the last decades: Michael Bishop, dean of the University of California San Francisco and laureate of the Nobel Prize for the discovery of oncogenes, who revolutionized cancer research, Jules Hoffmann, former Chairman of the French *Académie des Sciences* who was behind the discovery of innate immunity, Inder Verma, from the Salk Institute, one of the founding fathers of gene therapy, Fred Gage, from the Salk Institute, who discovered neural stem cells in the human brain, Iain Robinson, from the National Institute for Medical Research, who pioneered research on the hormones of the hypothalamus, Eric Kandel, from Columbia University in the City of New York and laureate of the Nobel Prize for his work on memory, as well as Stanislas Dehaene, Professor at the *Collège de France*, whose research has opened new perspectives on the understanding of human conscience.

The meeting will be chaired by two of the most prominent personalities in French science: Jean-Pierre Changeux, member of the *Académie des Sciences* who was behind basic research on acetylcholine receptors, and Nicole Le Douarin, pioneer of embryology research and perpetual secretary of the *Académie des Sciences*. Additional scientists who have also been instrumental in the evolution of knowledge, such as Professor Roger Guillemin, Nobel Prize Laureate of Medicine and Director of the Salk Institute, one of Ipsen's key partners, will also attend the symposium.

Jean-Luc Bélingard, Chairman & CEO of Ipsen, said: *“We are extremely proud and honored to welcome these key individuals who have significantly marked the life sciences landscape, to our new headquarters. The calibre of the scientists presenting at this meeting is testament to Ipsen’s longstanding commitment, alongside the academic community, to meet today’s new biomedical challenges. The drive to develop new drugs to treat the huge unmet medical needs we still see today requires strong collaboration between all stakeholders, including the academic community and the pharmaceutical industry.”*



About Ipsen

Ipsen is an innovation-driven international specialty pharmaceutical group with over 20 products on the market and a total worldwide staff of nearly 4,000. Its development strategy is based on a combination of specialty products, which are growth drivers, in targeted therapeutic areas (oncology, endocrinology and neuromuscular disorders), and primary care products which contribute significantly to its research financing. The location of its four Research & Development centres (Paris, Boston, Barcelona, London) and its peptide and protein engineering platform give the Group a competitive edge in gaining access to leading university research teams and highly qualified personnel. More than 700 people in R&D are dedicated to the discovery and development of innovative drugs for patient care. This strategy is also supported by an active policy of partnerships. In 2007, Research and Development expenditure was about €185 million, in excess of 20% of consolidated sales, which amounted to €920.5 million while total revenues amounted to €993.8 million. Ipsen's shares are traded on Segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150). Ipsen's shares are eligible to the "Service de Règlement Différé" ("SRD") and the Group is part of the SBF 120 index. For more information on Ipsen, visit our website at www.ipсен.com.

For further information:

Didier Véron

Director, Public Affairs and Corporate Communications

Tel.: +33 (0)1 58 33 51 16

Fax: +33 (0)1 58 33 50 58

E-mail: didier.veron@ipсен.com

David Schilansky

Investor Relations Officer

Tel.: +33 (0)1 58 33 51 30

Fax: +33 (0)1 58 33 50 63

E-mail: david.schilansky@ipсен.com